Obesity is a complex condition linked to over 200 health issues, making comprehensive treatment essential. At Form Health, we 'treat obesity first' to help patients achieve life-changing weight loss, improve health markers, and reduce healthcare costs associated with weight-related comorbidities. Each patient works with a doctor and Registered Dietitian to create a personalized plan that includes nutrition, physical activity, mindset shifts, and may incorporate FDA-approved medications. Is your organization looking for an impactful, cost-effective solution to address the rising costs of obesity and related metabolic diseases? Contact us at employers@formhealth.co to learn how we can help.
Form Health
Hospitals and Health Care
Boston, Massachusetts 4,366 followers
Form Health is the national leader in science-based obesity care.
About us
Form Health is the national leader in science-based obesity care. Our clinical care model consists of one-on-one, personalized care from a dedicated ABOM-certified physician and a CSOWM-certified Registered Dietitian, who develop individualized treatment plans that address nutrition, physical activity, mindset shifts, and include a prescription for FDA-approved medication, if appropriate. Form Health keeps safety, efficacy, and outcomes at the forefront as we incorporate the latest research and science into our approach. This means we’re always innovating, constantly getting smarter about the science of obesity care, relentlessly focusing on exceptional results, and calling out harmful practices that hold back progress. The result is life-changing outcomes for our patients and meaningful ROI for our enterprise partners. Form Health is in-network with national health plans. Learn more at formhealth.co.
- Website
-
http://formhealth.co
External link for Form Health
- Industry
- Hospitals and Health Care
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2019
Locations
-
Primary
Get directions
109 State St
5th Floore
Boston, Massachusetts 02109, US
Employees at Form Health
-
Rob Go
Co-Founder and Partner at NextView
-
Theresa Nute
Advising and creating go to market strategies health tech companies who work with Health Plans and Managed Care organizations.
-
Jeremy Weiskotten
Senior Product and Engineering Leader
-
Ethan Heffler
Lead Product Designer at Form Health
Updates
-
Chief Medical Officer Florencia Halperin reminds us of the dangers associated with compounded medications and the importance of working with medical professionals who prioritize patient safety. At Form Health, safety is our top priority. We do not endorse the use of compounded drugs due to significant quality and safety concerns. Our providers only prescribe FDA-approved medications when clinically appropriate. Is your organization seeking an obesity solution that puts patient safety first? Contact us at employers@formhealth.co to learn how we can help.
When I was a medical resident at Brigham and Women's Hospital I gave my first talk on the medical treatment of obesity. I proudly quoted data about commercial programs that were giants in the space, with decent published data about the benefits that structured lifestyle programs, based on education, tracking, accountability and support for behavior change. I encouraged fellow residents to manage obesity as a health condition, and to consider such programs as a tool in their tool box. Now I am watching as more and more of these reputable lifestyle change programs start to sell compounded medications, and I am truly worried. People with obesity have a medical condition, which carries tremendous stigma and increased health risks. The last thing they need is more health risk from "treatment"! This study highlights some of the craziness going on in the world - not just compounded, also fakes, sold, without prescriptions, purchases confirmed on WhatsApp. With all of this, US poison control centers report a 1500% increase in calls related to severe side effects of "semaglutide". Please encourage anyone you know, or care about, or employ, to use only FDA-approved medications with rigorous quality and safety testing and randomized trial data to support efficacy and safety!
Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases
jamanetwork.com
-
Did you know Form Health is in-network with national health plans and already making a difference for your members and clients? Members experience sustained weight loss and a reduction in costly weight-related comorbidities. Client organizations see prescription savings and lower healthcare costs, while offering a benefit that members highly value. If you're interested in learning how we can help you provide a clinical obesity management benefit that meets the needs of your members and clients, email healthplans@formhealth.co
Health Plans | Form Health
formhealth.co
-
Form Health CEO Evan Richardson spoke with Steve Kraus on The Heart of Healthcare Podcast about the impact of GLP-1s, the dangers of compounded medications, the importance of comprehensive clinical care, and how Form Health is leading the way in providing science-based obesity care. Check out the insightful conversation here:
The GLP-1 Weight Loss Revolution | Form Health CEO Evan Richardson — The Heart of Healthcare Podcast
heartofhealthcarepodcast.com
-
Form Health physician Lauren Lemieux, MD, FACP, DABOM shared recent clinical study results showing that GLP-1s can positively impact patients with diabetes and MASLD (formerly NASH). This study provides yet another example of how GLP-1 therapies can address metabolic conditions beyond obesity. At Form Health, our obesity medicine specialists treat obesity with a comprehensive, science-based approach that is individualized for each patient. Is your organization seeking an impactful and cost-effective solution to address the high cost of obesity and its metabolic disease? Contact us at employers@formhealth.co to learn how we can help.
Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NASH) is the most common chronic liver disease, affecting more than 1/3 of adults in the world! It can lead to end stage liver disease (cirrhosis), a need for liver transplantation and hepatocellular carcinoma. A recent study found that GLP-1 receptor agonist use was associated with a lower risk of developing cirrhosis and death in patients with MASLD (without cirrhosis) and type 2 diabetes. This study included over 15,000 patients with MASLD and type 2 diabetes who were taking a GLP-1 receptor agonist and subdivided those into with vs. without cirrhosis. The GLP-1 receptor agonists included in the study were exenatide, dulaglutide, liraglutide or semaglutide, and the majority were on semaglutide (75.6%). Note, however, that for patients who already had cirrhosis at the time of the study, there was not a statistically significant difference in terms of developing complications of cirrhosis or mortality compared to those not taking a GLP-1 receptor agonist. This study highlights the potential impact GLP-1 therapy could provide for patients with diabetes and MASLD, and the need for long-term randomized controlled trials in this patient population to confirm these benefits. Furthermore, it suggests (not surprisingly) that *prevention,* in this case before cirrhosis develops, is a more effective approach. https://lnkd.in/g3ayieuq MASLD stats: https://lnkd.in/gpneDeJR
GLP-1 Receptor Agonists and Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
jamanetwork.com
-
Chief Medical Officer Florencia Halperin explains why new research from the Cleveland Clinic underscores the need for comprehensive, science-based obesity care and why asynchronous prescribing and non-expert support fall short. Form Health partners with organizations to ensure that obesity medications are used appropriately under clinical supervision to ensure safety and maximum impact. Our physicians use severity-adjusted prescribing to help control Rx cost and deliver ROI. Contact us at employers@formhealth.co to learn how we can help provide an impactful and cost-effective solution to address the high cost of obesity and metabolic disease.
New research published this week from the Cleveland Clinic describes their "real world" results of the impact of GLP1 medications on weight. For semaglutide (Ozempic, Wegovy) it was significantly less than originally described in clinical trials. When I think about these results, and how complex it is to drive weight loss outcomes, I also think about the many conversations I am having with health benefits buyers. They have tough decisions to make. They are trying to understand what are best practices in clinical care when using these medicines, and how they can drive the greatest impact for dollars spent. I believe these results from a renown institution underscore that point solutions out there prescribing asynchronously, providing no supportive care or only from bots and/or unlicensed coaches, are never going to have what it takes to make real health impact. We need to arm patients with all of the science-based tools in the toolbox, ensure that the right patients are selected for treatment, and then allow reliable access to it. Most importantly, obesity like diabetes is a chronic and complex medical condition, and your partners should have the medical depth to support these patients and complex medical decision-making, and manage a rapidly evolving landscape in the treatment of metabolic disease. Also, we are excited to share some of Form's clinical results, so stay tuned for our live reporting from The Obesity Society annual meeting in early November!
One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice
jamanetwork.com
-
We’re heading to Chicago this Wednesday September 18 for the Midwest Business Group on Health Obesity Forum: "Keeping Up With the Ever-Changing Landscape of Obesity Management." Be sure to connect with Jen Cressman and Tom Kahl during the event to discover how Form Health can help your organization provide access to clinical obesity care with sustainable results and a strong ROI. Not attending but want to learn more? Email us at employers@formhealth.co.
-
-
Form Health reposted this
Amycretin is making waves as a novel, oral dual GLP-1/amylin receptor co-agonist for weight loss. In this early study, patients treated with the highest dose of amycretin lost and average of ~13% of their starting weight after 12 weeks. To put it in perspective, if a patient weighs 300 lbs, this would be losing 39 lbs in 3 months. Compare this to Wegovy (a GLP-1 receptor agonist), which showed an average of ~15% at 68 weeks in the STEP1 study . Amylin works similarly to GLP-1. They both slow gastric emptying and act on the brain to reduce appetite (https://lnkd.in/g-hs8PeH). We've already seen how combinations of incretin hormones like Zepbound, a dual GLP-1/GIP receptor agonist, can lead to significant weight loss. Obesity pharmacotherapy research and drug development continues to move in this direction of combination therapy with the hopes of better weight loss outcomes (ideally with fewer side effects). Keep in mind, this is an early study, and there are many important questions that remain unanswered at this time. For example, what is the quality and safety of such rapid and significant weight loss? Nevertheless, I am cautiously optimistic that the attention that these therapies receive will continue to support acceptance of obesity as a chronic disease that deserves (demands!) access to effective and safe treatments just like other common chronic diseases like hypertension and diabetes. https://lnkd.in/g8YQpmXf Amycretin abstract: https://lnkd.in/gYMEBNCG STEP1: https://lnkd.in/gUkxBZ5v
Novo Nordisk experimental obesity pill has mild-to-moderate side effects in trial
reuters.com
-
Chief Medical Officer Dr. Florencia Halperin and her co-panelists had a fantastic discussion at the Northeast Business Group on Health Pharmacy Benefits conference, covering the evolution of GLP-1s and how employers can effectively address obesity. Interested in learning how Form Health can help your organization provide access to clinical obesity care with sustainable results and a strong ROI? Contact us at employers@formhealth.co.
It was such a pleasure to speak today on "GLP-1s and Workplace Health: Balancing Costs and Benefits" with my incredible co-panelists, Dr Charles Smith, Chief Medical Officer North America, AON Health Solutions, Jeanne Walsh, Director of Benefits and Global Mobility, Boston Scientific, and Matt Houser, Senior Director, Cigna Pharmacy. We had such an engaged audience and good, tough questions. Thank you so much to NEBGH for the opportunity and for a great overall event!
-
-
We are in NYC and ready for today's Northeast Business Group on Health Pharmacy Benefits conference! Don't miss our CMO, Florencia Halperin, who will be speaking on the panel "GLP-1s: Medication evolution, trends in utilization, and what employers should be doing now" at 10:50 ET. Interested to learn how Form Health can support your organization provide access to clinical obesity care that delivers sustainable results and ROI? Stop by Table #6 to say hello to Jen Cressman or email employers @formhealth.co
-